Skip to content

The Influence of Vibrotactile Stimulation on Self-selected Walking Speed in People With Parkinson's Disease

The Influence of Vibrotactile Stimulation on Self-selected Walking Speed in People With Parkinson's Disease

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07308418
Enrollment
16
Registered
2025-12-29
Start date
2026-01-10
Completion date
2026-03-18
Last updated
2026-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease (PD)

Keywords

Parkinson's Disease, Gait analysis, Vibrotactile feedback

Brief summary

The study tests whether a smart shoe (NUSHU) that provides vibrotactile stimulation can improve walking speed in people with Parkinson's disease. Sixteen participants complete two short walking tests-with and without vibration-to compare gait speed, cadence, stride length, usability, and safety. It is a low-risk pilot study meant to generate first evidence for future research.

Detailed description

Study Overview This monozentric, prospective within-subject crossover pilot study investigates whether vibrotactile stimulation provided by the NUSHU, a CE-certified smart shoe, can influence spatiotemporal gait parameters-primarily self-selected walking speed-in adults with Parkinson's disease (PD). Parkinson's disease is often associated with reduced gait speed, shorter strides, and altered cadence, all of which are clinically relevant because they correlate with morbidity, fall risk, and quality of life. Rationale Earlier research suggests that vibration can positively influence gait by modulating proprioception, but existing devices have been impractical or clinically cumbersome. The NUSHU integrates sensors and vibration modules into an everyday shoe, enabling precise, phase-specific stimulation during the swing phase. Since no previous PD studies have tested this device, the project seeks to assess feasibility, safety, and initial efficacy signals. Participants Sixteen adults with a confirmed Parkinson's diagnosis will be recruited from multiple Physiozentrum Zürich locations. Key inclusion requirements include stable medication, ability to walk ≥ 200 m without resting, and sufficient understanding of German. Exclusion criteria include neuropathy, atypical parkinsonism, major comorbid gait disorders, or cognitive impairment that may interfere with procedures. Study Design and Procedures Participants attend a single 45-minute session consisting of: Informed consent and eligibility assessment Instruction on NUSHU use Two 2-minute walking tests (with and without vibration), in randomized order A 15-minute washout between tests Completion of the System-Usability-Scale (SUS) questionnaire Continuous monitoring and documentation of safety events and perceived stability The assessor is blinded regarding the stimulation condition to reduce bias. Outcomes Primary outcome: Difference in self-selected gait speed between vibration vs. no-vibration conditions. Secondary outcomes: * Cadence * Stride length * Usability (SUS-DE) * Safety observations and subjective stability ratings Statistics As an exploratory pilot, the study is not powered for confirmatory conclusions. Paired statistical tests (t-test or Wilcoxon) will evaluate within-subject differences. Descriptive methods and Bonferroni-corrected secondary analyses will complement the primary evaluation. Ethics & Risk Classified as Risk Category A, the study involves minimal risk, mainly the normal risk associated with walking. Strict inclusion criteria and supervised testing aim to reduce fall risk. Data will be pseudonymized and securely stored. Although participants receive no direct clinical benefit, the findings will support future research on technology-assisted mobility strategies for PD. Purpose: * Overall, the study aims to understand: * The short-term effect of vibrotactile stimulation on gait * The feasibility, usability, and safety of NUSHU in a PD population * Whether larger, controlled trials are justified

Interventions

DEVICEVibrotactile feedback during walking

NUSHU smart shoes give real time gait feedback during walking.

Sponsors

Magnes AG
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* A medically confirmed diagnosis of Parkinson's disease on the physiotherapy prescription. * Stable medication for at least four weeks (no change in dopaminergic therapy). * The ability to walk at least 200 metres without stopping. * Minimum age: 18 years * Sufficient knowledge of German to understand the study information and complete the questionnaires. * Written informed consent form

Exclusion criteria

* Atypical or secondary Parkinsonism * Sensory disturbances in the feet (e.g. polyneuropathy). * Other neurological, orthopaedic or internal medical conditions that significantly affect walking * Cognitive impairments that interfere with understanding the study information or following instructions

Design outcomes

Primary

MeasureTime frameDescription
Change in self-selected walking speed (m/s)Once during 120 secondsChange in self-selected walking speed (m/s), measured over a 2-minute walking test with and without stimulation by the NUSHU. Walking speed is measured in m/s as a continuous metric variable, which is an objective and established way of measuring walking speed. The calculation is performed by dividing the total distance covered by the time in seconds (120 seconds).
Change in self-selected gait speedOne visit of 45 minutes

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 7, 2026